5 results
The primary objective is to compare a 12-month antithrombotic regimen of edoxaban in combination with clopidogrel or another P2Y12 antagonist against a regimen of a vitamin K antagonist (VKA) in combination with clopidogrel or another P2Y12…
-To identify a safe dose of MK-8408 in HCV infected patients that mediates a 3Log10 reduction-To evaluate safety and tolerability of MK-8408 administered for 5 consecutive days-To evaluate the plasma pharmacokinetic profile of multiple oral doses of…
Primary Objective:* Assess the diagnostic efficacy (sensitivity and specificity) of Flurpiridaz (18F) Injection PET myocardial perfusion imaging (MPI) in the detection of significant CAD, as defined by invasive coronary angiography (ICA), in…
The aim of this study is to assess the pharmacodynamic effects of different P2Y12 inhibiting therapy (clopdiogrel vs ticagrelor) in patients at high risk for HPR identified according to the ABCD-GENE score in PCI treated patients also requiring OAC…
The primary efficacy endpoint is to assess ischemic risk of genotype-guided clopidogrel monotherapy during the first 6 months following successful PCI in NSTE-ACS patients.The primary safety endpoint is to assess bleeding risk of genotype-guided…